American Regent vs. Zydus: Selenious Acid Patent Infringement Case Consolidated
What would you like to do next?
Choose your path based on your current needs:
Introduction: A Multi-Front Patent Battle Over Intravenous Selenium
In December 2024, American Regent, Inc. (ARI) launched one of the most sweeping pharmaceutical patent enforcement campaigns of the year — filing simultaneous infringement actions against more than a dozen generic drug manufacturers in a single day. Among those targeted was Zydus Pharmaceuticals (USA) Inc., named in Case No. 2:24-cv-11133 before the United States District Court for the District of New Jersey.
The dispute centers on US Patent No. 12150957B2, covering ARI’s proprietary selenious acid intravenous (IV) solutions — critical micronutrient formulations used in parenteral nutrition. Within 21 days of filing, the case against Zydus was closed — not through dismissal or settlement, but through consolidation into the broader In re Selenious Acid Litigation (Civil Action No. 2:24-cv-7791), signaling a coordinated, large-scale selenious acid patent infringement litigation strategy with significant implications for the generic pharmaceutical industry.
For patent attorneys, IP professionals, and R&D teams operating in the pharmaceutical space, this case offers a masterclass in multi-defendant patent enforcement and procedural consolidation strategy.
📋 Case Summary
| Case Name | American Regent, Inc. v. Zydus Pharmaceuticals (USA) Inc. |
| Case Number | 2:24-cv-11133 (D.N.J.) |
| Court | United States District Court for the District of New Jersey |
| Duration | Dec 13, 2024 – Jan 3, 2025 21 days |
| Outcome | Procedurally Closed – Consolidated |
| Patents at Issue | |
| Accused Products | Zydus’s selenious acid solutions (12 mcg/2 mL, 60 mcg/mL, 600 mcg/10 mL) |
Case Overview
The Parties
⚖️ Plaintiff
New York-based specialty pharmaceutical company and a subsidiary of Luitpold Pharmaceuticals. Focuses on injectable drugs and micronutrient therapies.
🛡️ Defendant
U.S. arm of Zydus Cadila, one of India’s largest generic pharmaceutical manufacturers, with an active Abbreviated New Drug Application (ANDA) pipeline.
The Patent at Issue
This case centers on a crucial patent protecting intravenous selenious acid solutions:
- • US12150957B2 — Covering specific concentration formulations of selenious acid for IV administration, a niche but clinically essential segment of hospital and critical care pharmacotherapy.
The Accused Products
ARI alleged infringement based on Zydus’s selenious acid solutions, intravenous, in three configurations, mirroring ARI’s branded formulations:
- • 12 mcg/2 mL
- • 60 mcg/mL
- • 600 mcg/10 mL
Litigation Timeline & Procedural History
The speed of consolidation — just 21 days from filing to closure of the individual docket — is procedurally significant. ARI filed thirteen related actions on a single date (December 13, 2024), targeting defendants including Accord Healthcare, Aspiro Pharma, Cipla, Dr. Reddy’s Laboratories, Gland Pharma, Hikma Pharmaceuticals, RK Pharma, Somerset Therapeutics, Sun Pharmaceutical Industries, Xiromed, and Zydus.
The venue selection — District of New Jersey — is strategically deliberate. New Jersey is a preferred forum for Hatch-Waxman pharmaceutical patent disputes due to its experienced judiciary, pharmaceutical industry proximity, and established case management protocols for complex multi-party IP litigation.
All parties jointly requested consolidation, indicating cooperation at the procedural level even amid adversarial postures on the merits. Going forward, all filings proceed under the consolidated caption in Civil Action No. 2:24-cv-7791.
Case documents available via PatSnap Eureka. Patent details searchable through PatSnap’s platform.
Developing a similar pharmaceutical product?
Check if your formulation might infringe this or related patents.
The Verdict & Legal Analysis
Outcome
Case No. 2:24-cv-11133 was closed on January 3, 2025, with a basis of termination recorded as consolidation into the lead docket, In re Selenious Acid Litigation (2:24-cv-7791). No damages were assessed, no injunctions were entered, and no merits determination was reached in this individual action. The case’s closure reflects procedural efficiency, not substantive resolution.
Verdict Cause Analysis
The infringement action arises almost certainly under the Hatch-Waxman Act (21 U.S.C. § 355(j)), the framework governing ANDA-based patent disputes for generic pharmaceuticals. Under Hatch-Waxman, a generic manufacturer filing an ANDA with a Paragraph IV certification — asserting that a listed patent is invalid or will not be infringed — automatically triggers the patentee’s right to sue within 45 days, initiating a 30-month regulatory stay on FDA approval.
ARI’s simultaneous filing against thirteen defendants on a single day strongly indicates that multiple ANDA filers submitted Paragraph IV certifications around the same period, triggering coordinated enforcement. This is a well-recognized patent assertion strategy: file early, file broadly, consolidate for efficiency, and use the 30-month stay as commercial protection while litigation proceeds.
Legal Significance
Several legally significant dimensions emerge:
- • Claim Scope for Concentration-Specific Formulations: Courts in Hatch-Waxman cases frequently grapple with whether concentration ranges in pharmaceutical patents are sufficiently specific to support infringement findings. The overlap between ARI’s claimed formulations and Zydus’s accused products — identical concentrations — presents a strong prima facie literal infringement argument.
- • Validity Challenges Anticipated: Generic defendants in consolidated Hatch-Waxman proceedings routinely assert invalidity defenses, including obviousness (35 U.S.C. § 103) and lack of written description (35 U.S.C. § 112). Expect defendants to challenge whether the specific selenious acid concentrations represent a non-obvious advance over prior art.
- • Consolidation Precedent: The In re Selenious Acid Litigation consolidation mirrors case management structures used in other multi-ANDA patent disputes, offering a template for similarly complex pharmaceutical enforcement campaigns.
Filing a pharmaceutical patent?
Learn from this case. Use AI to draft stronger claims that can withstand litigation.
Power Your Patent Strategy with PatSnap Eureka IP
From novelty searches to patent drafting, PatSnap Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical formulation design. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation for pharmaceutical IP.
- View all related patents in the parenteral nutrition space
- See which companies are most active in formulation patents
- Understand claim construction patterns for concentration claims
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical technology or product.
- Input your formulation details or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Selenious acid IV formulations at specific concentrations
1 Patent at Issue
Targeted in 13 related infringement actions
Limited Design-Arounds
Due to clinical necessity of specific concentrations
✅ Key Takeaways
For Patent Attorneys & Litigators
Simultaneous multi-defendant Hatch-Waxman filing with immediate consolidation is an increasingly common and efficient enforcement architecture.
Search related case law →Concentration-specific pharmaceutical formulation claims can anchor strong literal infringement arguments.
Explore precedents →Expect invalidity challenges centered on obviousness and written description as primary defense strategies.
View invalidity reports →For IP Professionals
Monitor In re Selenious Acid Litigation as a bellwether for formulation patent enforceability in parenteral nutrition products.
Track this case on PatSnap →Portfolio strategy should include concentration and dosage-specific claims alongside composition patents for comprehensive protection.
Analyze patent portfolios →For R&D Teams
FTO clearance for injectable pharmaceutical products must include granular formulation patent searches.
Start FTO analysis for my product →Early-stage product design should evaluate whether clinically necessary concentrations overlap with existing patent claims.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.